Kelfer 250 Capsule contains Deferiprone 250 mg, an oral iron chelator indicated for the treatment of iron overload conditions, particularly in patients with thalassemia major and other chronic anemias requiring regular blood transfusions. Deferiprone acts by binding excess free iron in the bloodstream, forming a complex that is subsequently excreted primarily via the urine, thereby reducing iron accumulation in vital organs such as the heart, liver, and endocrine glands. This mechanism helps prevent complications associated with iron overload, including cardiomyopathy, liver cirrhosis, and endocrine dysfunction. Kelfer 250 is typically administered under strict medical supervision with regular monitoring of serum ferritin levels and complete blood counts to assess efficacy and detect potential adverse effects. Common side effects may include gastrointestinal disturbances, arthralgia, and transient neutropenia; however, agranulocytosis is a rare but serious risk requiring immediate medical attention. The dosage regimen should be individualized based on patient response and tolerability. Kelfer 250 Capsule is contraindicated in patients with hypersensitivity to Deferiprone or those with severe hepatic or renal impairment. It is essential to adhere to prescribed dosing and monitoring protocols to optimize therapeutic outcomes and minimize risks associated with iron chelation therapy.